Literature DB >> 32139011

Reconstructing the evolutionary history of multiple myeloma.

Francesco Maura1, Even H Rustad2, Eileen M Boyle3, Gareth J Morgan4.   

Abstract

Multiple myeloma is the second most common lymphoproliferative disorder, characterized by aberrant expansion of monoclonal plasma cells. In the last years, thanks to novel next generation sequencing technologies, multiple myeloma has emerged as one of the most complex hematological cancers, shaped over time by the activity of multiple mutational processes and by the acquisition of key driver events. In this review, we describe how whole genome sequencing is emerging as a key technology to decipher this complexity at every stage of myeloma development: precursors, diagnosis and relapsed/refractory. Defining the time windows when driver events are acquired improves our understanding of cancer etiology and paves the way for early diagnosis and ultimately prevention.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Driver events; Multiple myeloma; Timing; Whole genome sequencing

Mesh:

Year:  2020        PMID: 32139011      PMCID: PMC7389821          DOI: 10.1016/j.beha.2020.101145

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  46 in total

1.  Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.

Authors:  Luca Agnelli; Silvio Bicciato; Michela Mattioli; Sonia Fabris; Daniela Intini; Donata Verdelli; Luca Baldini; Fortunato Morabito; Vincenzo Callea; Luigia Lombardi; Antonino Neri
Journal:  J Clin Oncol       Date:  2005-08-29       Impact factor: 44.544

Review 2.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

3.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

4.  Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.

Authors:  Robert A Kyle; Dirk R Larson; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; James R Cerhan; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2018-01-18       Impact factor: 91.245

5.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.

Authors:  Brian A Walker; Christopher P Wardell; Alex Murison; Eileen M Boyle; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; Lorenzo Melchor; Charlotte Pawlyn; Martin F Kaiser; David C Johnson; Ya-Wei Qiang; John R Jones; David A Cairns; Walter M Gregory; Roger G Owen; Gordon Cook; Mark T Drayson; Graham H Jackson; Faith E Davies; Gareth J Morgan
Journal:  Nat Commun       Date:  2015-04-23       Impact factor: 14.919

Review 6.  Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma.

Authors:  Benjamin G Barwick; Vikas A Gupta; Paula M Vertino; Lawrence H Boise
Journal:  Front Immunol       Date:  2019-05-21       Impact factor: 7.561

7.  Genomic landscape and chronological reconstruction of driver events in multiple myeloma.

Authors:  Francesco Maura; Niccoló Bolli; Nicos Angelopoulos; Kevin J Dawson; Daniel Leongamornlert; Inigo Martincorena; Thomas J Mitchell; Anthony Fullam; Santiago Gonzalez; Raphael Szalat; Federico Abascal; Bernardo Rodriguez-Martin; Mehmet Kemal Samur; Dominik Glodzik; Marco Roncador; Mariateresa Fulciniti; Yu Tzu Tai; Stephane Minvielle; Florence Magrangeas; Philippe Moreau; Paolo Corradini; Kenneth C Anderson; Jose M C Tubio; David C Wedge; Moritz Gerstung; Hervé Avet-Loiseau; Nikhil Munshi; Peter J Campbell
Journal:  Nat Commun       Date:  2019-08-23       Impact factor: 14.919

8.  The repertoire of mutational signatures in human cancer.

Authors:  Ludmil B Alexandrov; Jaegil Kim; Gad Getz; Steven G Rozen; Michael R Stratton; Nicholas J Haradhvala; Mi Ni Huang; Alvin Wei Tian Ng; Yang Wu; Arnoud Boot; Kyle R Covington; Dmitry A Gordenin; Erik N Bergstrom; S M Ashiqul Islam; Nuria Lopez-Bigas; Leszek J Klimczak; John R McPherson; Sandro Morganella; Radhakrishnan Sabarinathan; David A Wheeler; Ville Mustonen
Journal:  Nature       Date:  2020-02-05       Impact factor: 49.962

9.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Authors:  Jens G Lohr; Petar Stojanov; Scott L Carter; Peter Cruz-Gordillo; Michael S Lawrence; Daniel Auclair; Carrie Sougnez; Birgit Knoechel; Joshua Gould; Gordon Saksena; Kristian Cibulskis; Aaron McKenna; Michael A Chapman; Ravid Straussman; Joan Levy; Louise M Perkins; Jonathan J Keats; Steven E Schumacher; Mara Rosenberg; Gad Getz; Todd R Golub
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

10.  A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Authors:  Brian A Walker; Konstantinos Mavrommatis; Christopher P Wardell; T Cody Ashby; Michael Bauer; Faith Davies; Adam Rosenthal; Hongwei Wang; Pingping Qu; Antje Hoering; Mehmet Samur; Fadi Towfic; Maria Ortiz; Erin Flynt; Zhinuan Yu; Zhihong Yang; Dan Rozelle; John Obenauer; Matthew Trotter; Daniel Auclair; Jonathan Keats; Niccolo Bolli; Mariateresa Fulciniti; Raphael Szalat; Phillipe Moreau; Brian Durie; A Keith Stewart; Hartmut Goldschmidt; Marc S Raab; Hermann Einsele; Pieter Sonneveld; Jesus San Miguel; Sagar Lonial; Graham H Jackson; Kenneth C Anderson; Herve Avet-Loiseau; Nikhil Munshi; Anjan Thakurta; Gareth Morgan
Journal:  Leukemia       Date:  2018-07-02       Impact factor: 11.528

View more
  5 in total

1.  Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001.

Authors:  Francesco Maura; Benjamin Diamond; Kylee H Maclachlan; Andriy Derkach; Venkata D Yellapantula; Even H Rustad; Malin Hultcrantz; Urvi A Shah; Jessica Hong; Heather J Landau; Christine A Iacobuzio-Donahue; Elli Papaemmanuil; Shani Irby; Laura Crowley; Michael Crane; Mayris P Webber; David G Goldfarb; Rachel Zeig-Owens; Orsi Giricz; Amit Verma; David J Prezant; Ahmet Dogan; Sohrab P Shah; Yanming Zhang; Ola Landgren
Journal:  Clin Cancer Res       Date:  2021-01-27       Impact factor: 13.801

2.  Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.

Authors:  Bénedith Oben; Guy Froyen; Kylee H Maclachlan; Daniel Leongamornlert; Federico Abascal; Binbin Zheng-Lin; Venkata Yellapantula; Andriy Derkach; Ellen Geerdens; Benjamin T Diamond; Ingrid Arijs; Brigitte Maes; Kimberly Vanhees; Malin Hultcrantz; Elisabet E Manasanch; Dickran Kazandjian; Alexander Lesokhin; Ahmet Dogan; Yanming Zhang; Aneta Mikulasova; Brian Walker; Gareth Morgan; Peter J Campbell; Ola Landgren; Jean-Luc Rummens; Niccolò Bolli; Francesco Maura
Journal:  Nat Commun       Date:  2021-03-25       Impact factor: 14.919

Review 3.  Genome Instability in Multiple Myeloma: Facts and Factors.

Authors:  Anna Y Aksenova; Anna S Zhuk; Artem G Lada; Irina V Zotova; Elena I Stepchenkova; Ivan I Kostroma; Sergey V Gritsaev; Youri I Pavlov
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

4.  Mouse tumor susceptibility genes identify drug combinations for multiple myeloma.

Authors:  Shuling Zhang; Wendy DuBois; Ke Zhang; John K Simmons; V Keith Hughitt; Sayeh Gorjifard; Snehal Gaikwad; Tyler J Peat; Beverly A Mock
Journal:  J Cancer Metastasis Treat       Date:  2020-07-26

5.  Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data.

Authors:  Amit Katiyar; Gurvinder Kaur; Lata Rani; Lingaraja Jena; Harpreet Singh; Lalit Kumar; Atul Sharma; Punit Kaur; Ritu Gupta
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.